Health Catalyst (HCAT) Q4 Earnings: What To Expect

Healthcare data analytics company Health Catalyst (NASDAQ:HCAT) will be reporting results this Thursday after market close. Here’s what to look for.

Health Catalyst beat analysts’ revenue expectations last quarter, reporting revenues of $76.32 million, flat year on year. It was a slower quarter for the company, with revenue guidance for next quarter missing analysts’ expectations significantly and EBITDA guidance for next quarter missing analysts’ expectations significantly.

Is Health Catalyst a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Health Catalyst’s revenue to decline 7% year on year, a reversal from the 6% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Health Catalyst rarely misses Wall Street’s revenue estimates.

Looking at Health Catalyst’s peers in the data analytics segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Palantir Technologies delivered year-on-year revenue growth of 70%, beating analysts’ expectations by 4.9%, and Strategy reported revenues up 1.9%, topping estimates by 0.6%. Palantir Technologies traded up 6.8% following the results while Strategy was also up 26.1%.

Read our full analysis of Palantir Technologies’s results here and Strategy’s results here.

Investors in the data analytics segment have had steady hands going into earnings, with share prices flat over the last month. Health Catalyst is down 15.5% during the same time and is heading into earnings with an average analyst price target of $3.88 (compared to the current share price of $1.83).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.